© The Author 2006. Published by Oxford University Press.
ARTICLE |
Retrospective Cost-effectiveness Analysis of Screening Mammography
Affiliations of authors: Center for Risk Analysis, Harvard School of Public Health, Boston, MA (NKS); Department of Actuarial Science and Risk Management (MAR), Department of Biostatistics and Medical Informatics (MAR), Department of Population Health Sciences (ATD, MAS, DGF), Department of Industrial and Systems Engineering (SMR, DGF), University of Wisconsin, Madison, WI; University of Wisconsin Comprehensive Cancer Center, Madison, WI (MAR, ATD, MAS, DGF)
Correspondence to: Natasha K. Stout, PhD, Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Ave., Boston, MA 02115 (e-mail: nstout{at}hsph.harvard.edu).
Background: Many guidelines recommend screening mammography every 1–2 years for women older than 40 years; more than 70% of women now participate in routine screening. No studies have examined the societal impact of screening practices over the past decade in the United States on costs and quality-adjusted life-years (QALYs). We performed a retrospective cost-effectiveness analysis comparing actual and alternative screening mammography scenarios. Methods: We used a discrete-event simulation model of breast cancer epidemiology to estimate the costs and the number of QALYs that were associated with observed screening mammography patterns in the United States from 1990 to 2000 for women aged 40 years or older. We also estimated costs and QALYS for no screening and for 64 alternative screening scenarios. Incremental cost-effectiveness ratios were computed. Sensitivity analyses were performed on key parameters. Results: Actual U.S. screening patterns from 1990 to 2000 accrued 947.5 million QALYs and cost $166 billion over the lifetimes of the screened women, resulting in a gain of 1.7 million QALYs for an additional cost of $62.5 billion compared with no screening. Among those polices that were not dominated—i.e., for which no alternative existed that produced more QALYs for lower costs—screening all women aged 40–80 years annually per some U.S. guidelines was the most expensive option, costing $58 000 per additional QALY gained compared with the next most costly alternative, screening all women aged 45–80 years annually. Many alternative screening scenarios generated more QALYs for less cost (with savings up to $6 billion) than actual screening patterns over the study period. Sensitivity analysis showed that conclusions about the cost-effectiveness of screening mammography policies were highly sensitive to small, short-term detrimental effects on quality of life from the screening test itself. Conclusions: Choosing among the efficient policies to guide current screening recommendations requires consideration of costs to promote participation in screening and measurement of acute quality-of-life effects of mammography.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Kim, J. Ortendahl, and S. J. Goldie Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States Ann Intern Med, October 20, 2009; 151(8): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Valenstein, D. Eisenberg, J. F. McCarthy, K. L. Austin, D. Ganoczy, H. M. Kim, K. Zivin, J. D. Piette, M. Olfson, and F. C. Blow Service Implications of Providing Intensive Monitoring During High-Risk Periods for Suicide Among VA Patients With Depression Psychiatr Serv, April 1, 2009; 60(4): 439 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Ahern and Y. Shen Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 718 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Wilkins, L. Teixeira, C. Julien, F. Guimiot, and H. Jernstrom Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med., September 25, 2008; 359(13): 1406 - 1407. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Cheung, S. A. Roman, T. S. Wang, H. D. Walker, and J. A. Sosa Calcitonin Measurement in the Evaluation of Thyroid Nodules in the United States: A Cost-Effectiveness and Decision Analysis J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2173 - 2180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Mandelblatt, J. Cullen, W. F. Lawrence, A. L. Stanton, B. Yi, L. Kwan, and P. A. Ganz Economic Evaluation Alongside a Clinical Trial of Psycho-Educational Interventions to Improve Adjustment to Survivorship Among Patients With Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1684 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N.A. Tosteson, N. K. Stout, D. G. Fryback, S. Acharyya, B. A. Herman, L. G. Hannah, E. D. Pisano, and for the DMIST Investigators Cost-Effectiveness of Digital Mammography Breast Cancer Screening Ann Intern Med, January 1, 2008; 148(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Kim, R. A. P. Scott, H. A. Ashton, S. G. Thompson, and for the Multicentre Aneurysm Screening Study Group A Sustained Mortality Benefit from Screening for Abdominal Aortic Aneurysm Ann Intern Med, May 15, 2007; 146(10): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Knudsen, P. M. McMahon, and G. S. Gazelle Use of Modeling to Evaluate the Cost-Effectiveness of Cancer Screening Programs J. Clin. Oncol., January 10, 2007; 25(2): 203 - 208. [Abstract] [Full Text] [PDF]
|
|